Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ARCHIVE
ARCHIVE
- NDA Review System Should Be Reformed as Part of Administrative Reform: New ELD Director
February 12, 2001
- Demographic Estimates for 2000 Show More Births: Koseisho
February 12, 2001
- EMA Proposes Measures to Encourage Use of Generics
February 12, 2001
- Korosho to Issue Notification in May to Introduce CTD
February 12, 2001
- Record-low Population Growth Rate Marked: Nat'l Census
February 12, 2001
- Senshu Yakuhin Restarts Business as Subsidiary of Kuraya Sanseido
February 12, 2001
- Kemporen Calls For Elimination of Financial Contribution to Elderly Healthcare
February 12, 2001
- 39 Monodrugs, 2 Combination Drugs Designated: Quality Reevaluation
February 12, 2001
- Mochida to Prevail through R&D, Alliance, Emphasis on Results
February 12, 2001
- Keisansho to Promote Healthcare Services as Industry
February 12, 2001
- REGULATORY NEWS IN BRIEF -2-
February 12, 2001
- Dainippon to Withdraw Aleviatin Fine Granules
February 12, 2001
- Drug Makers Must Assume Full Responsibility for Their Products
February 12, 2001
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
February 12, 2001
- Bayer Yakuhin, Meiji Seika to Comarket Ciproxan
February 12, 2001
- Japan Not to Introduce Inactivated Vaccine against Polio
February 12, 2001
- Combination Therapy with Protopic, Steroid Reported: Fujisawa Seminar
February 12, 2001
- Kyorin Establishes Subsidiary to Gain Foothold in US Market
February 12, 2001
- Serious ADR Reported for Sarpogrelate
February 12, 2001
- Daiichi Starts Drug Discovery Research in New Laboratory
February 12, 2001
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…